Search clinical trials for: ABT-888

Total 4619 results

Institut de Recherches Internationales Servier

Active, not recruiting

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Recurrent Glioma | Grade 2 Glioma | Residual Glioma

United States, Canada, Spain, Italy, United Kingdom, Switzerland, Israel, Japan, Netherlands, Germany, France
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (305)

Plaque Psoriasis

United States
University of Alabama at Birmingham

Completed

A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme

Brain Tumor

United States
Abbott

Completed

Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease

Chronic Kidney Disease

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Advanced Renal Cell Carcinoma | Unresectable Renal Cell Carcinoma

United States
AbbVie

Completed

Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Untreated Metastatic Colorectal Cancer
National Cancer Institute (NCI)

Completed

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Advanced Malignant Solid Neoplasm

United States
AbbVie

Completed

ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

Chronic Hepatitis C Virus (HCV)
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)

Hypertension | Dyslipidemias

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)

Hypertension and Dyslipidemia

Korea, Republic of
Lumy Sawaki

Completed

Sensory-driven Motor Recovery in Poorly Recovered Subacute Stroke Patients

Stroke | Cerebrovascular Accident
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects

Chronic Hepatitis b

Korea, Republic of
Chong Kun Dang Pharmaceutical

Unknown

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects

Chronic Hepatitis b

Korea, Republic of
Proteostasis Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
Lumy Sawaki

Completed

Enhancing Plasticity in Stroke Patients With Severe Motor Deficit

Stroke | Cerebrovascular Accident
AbbVie

Completed

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (MAGELLAN-3)

Hepatitis C Virus Infection

United States, Australia, Canada, China, Germany, Korea, Republic of, New Zealand, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
AbbVie

Completed

A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)

Psoriatic Arthritis
Millennium Pharmaceuticals, Inc.

Completed

A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants

Healthy Volunteers

United States
Takeda

Active, not recruiting

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Spain, Korea, Republic of, Taiwan, Japan, China, Italy, Germany, United Kingdom, Puerto Rico
Takeda

Terminated

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants

Healthy Volunteers

United States
University of British Columbia

Completed

Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists

Influenza Vaccination in Seniors

Canada
AstraZeneca

Completed

Interaction Between ABT-335, Rosuvastatin and Warfarin

Healthy

United States
Southern Europe New Drug Organization
Clinical Trial Unit Ente Ospedaliero Cantonale

Completed

Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer (S10PANI01)

Advanced Head and Neck Squamous Cancer
Yale University

Completed

A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

CTCL

United States
AbbVie (prior sponsor, Abbott)

Completed

Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States, Australia, Israel, Poland, Ukraine
Abbott
Genentech, Inc.

Completed

Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects

Healthy Female Subjects

United States
King Faisal University
Mansoura University

Completed

Non-dependent Lung High Frequency Positive Pressure Ventilation (HFPPV) and Right Ventricular Function

Lung Diseases | Esophageal Diseases

Egypt
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers

Healthy

Korea, Republic of
Baxalta now part of Shire
Takeda Development Center Americas, Inc.; Baxalta Innovations GmbH, now part...

Active, not recruiting

A Study of BAX 888 in Male Adults With Severe Hemophilia A

Hemophilia A

United States, Spain, Hungary, Italy, Germany, Austria, France
AbbVie

Completed

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

Multiple Sclerosis (MS)

United States, Canada
AbbVie
Genentech, Inc.

Completed

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States, Australia
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies

Small Cell Lung Carcinoma | Small Cell Lung Cancer

United States, Canada, United Kingdom
Kerry Rogers
Janssen Research & Development, LLC

Withdrawn

Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Chronic Lymphocytic Leukemia | Loss of Chromosome 17p
Abbott

Completed

Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.

Hypogonadal Males

United States
Andarix Pharmaceuticals

Recruiting

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Carcinoma, Small Cell | Neoplasm Recurrence, Local

United States
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348

Hypertension and Dyslipidemia

Korea, Republic of
AbbVie

Completed

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Lymphoblastic Lymphoma | Acute Lymphoblastic Leukemia (ALL)

United States, Australia
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

Chronic Lymphocytic Leukemia | Ibrutinib Resistance

United States
Steven E. Coutre

Completed

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Cocrystal Pharma, Inc.
Cocrystal Pharma Australia Pty Ltd.; Nucleus Network Pty Ltd.; Beyond Drug Development... and other collaborators

Recruiting

CDI-988 Safety Study in Healthy Participants

Healthy Volunteers

Australia
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Compare the Pharmacokinetics and Tolerability of CKD-348 (CKD-348)

Hypertension | Dyslipidemias

Korea, Republic of
National Institute of Diabetes and Digestive and...

Completed

Development of Limited Contact CBT Treatment for IBS

IBS

United States
Abbott

Completed

Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.

Dyslipidemia | Coronary Heart Disease | Mixed Dyslipidemia

United States
National Cancer Institute (NCI)

Terminated

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | Recurrent Lung Small Cell Carcinoma | Stage IIIA Lung Small Cell Carcinoma AJCC v7 | Stage IIIB Lung Small Cell Carcinoma AJCC v7 | Stage IV Lung Small Cell... and other conditions

United States
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Healthy Subjects

Netherlands
AbbVie

Available

Expanded Access to Venetoclax

Multiple Myeloma | Non-Hodgkin's Lymphoma | Amyloidosis | Chronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Plasma Cell Leukemia
AbbVie

Completed

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms (CisCP)

Chronic Pancreatitis

United States
Fondazione Italiana Linfomi - ETS

Terminated

Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

T-Cell Lymphoma Relapsed | T-Cell Lymphoma Refractory

Italy
AbbVie

Completed

Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers

Healthy Volunteers

United States
Peter MacCallum Cancer Centre, Australia

Active, not recruiting

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) (AIM)

Mantle Cell Lymphoma

Australia

Search clinical trials for: ABT-888

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations